Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.

(2021) Ghassan K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

(2021) Angela Lamarca et al.   LANCET ONCOLOGY

Molecular targeted therapies: Ready for “prime time” in biliary tract cancer

(2020) Angela Lamarca et al.   JOURNAL OF HEPATOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends

(2020) Mohamed M. Gad et al.   Clinics and Research in Hepatology and Gastroenterology

SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis

(2020) M. Javle et al.   ANNALS OF ONCOLOGY

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

(2020) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

(2020) Yung Lyou et al.   EUROPEAN UROLOGY

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, And Management Guidelines

(2020) Mario E. Lacouture et al.   ONCOLOGIST

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

(2020) M. Teresa Magone et al.   OPHTHALMOLOGY

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

(2020) Angela Lamarca et al.   Journal of Clinical Medicine

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

(2019) Maeve A. Lowery et al.   CANCER

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma

(2019) Richard D Kim et al.   Cancer Discovery

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems

(2017) Ze-Wu Meng et al.   MEDICINE

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

Biliary cancer: Utility of next-generation sequencing for clinical management

(2016) Milind Javle et al.   CANCER

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

(2015) Jeffrey S. Ross et al.   CANCER

Genomic spectra of biliary tract cancer

(2015) Hiromi Nakamura et al.   NATURE GENETICS

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

(2011) O. Amit et al.   EUROPEAN JOURNAL OF CANCER

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE